<DOC>
	<DOCNO>NCT01231555</DOCNO>
	<brief_summary>This 96 week , Phase 2b study 150 HIV-1 infected antiretroviral ( ART ) naive adult subject consist dose-ranging evaluation GSK2248761 blind dose 100 mg 200 mg daily control arm open-label efavirenz ( EFV ) 600 mg daily . The background ART 3 arm choose Investigators either abacavir/lamivudine [ ABC/3TC ] tenofovir/emtricitabine [ TDF/FTC ] fix dose combination ( FDC ) tablet . Antiviral activity , safety , PK , development viral resistance evaluate .</brief_summary>
	<brief_title>Dose-finding Study GSK2248761 Antiretroviral Therapy-Naive Subjects ( SIGNET )</brief_title>
	<detailed_description>Study SGN113404 phase 2b randomize , partially blind , multicenter , parallel group , dose-ranging study . The study conduct approximately 150 HIV-1 infected ART na√Øve subject . The background NRTIs co-administered GSK2248761 EFV select Investigators prior randomization either abacavir/lamivudine ( ABC/3TC ) tenofovir/emtricitabine ( TDF/FTC ) fix dose combination ( FDC ) tablet . Subjects participate Screening period ( Day -28 Day -1 ) . Subjects may re-screened . Subjects randomize 1:1:1 receive 100 mg GSK2248761 daily ( 50 subject ) , 200 mg GSK2248761 daily ( 50 subject ) 600 mg EFV daily ( 50 subject ) . All three arm combine either 300 mg/200 mg TDF/FTC 600 mg/300 mg ABC/3TC , chosen Investigator . The Investigators subject blind dose GSK2248761 administer know whether receive EFV GSK2248761 . The randomization stratify HIV-1 viral load ( VL ) screening , &lt; 100,000 copies/mL &gt; / 100,000 copies/mL well choice backbone NRTI , TDF/FTC ABC/3TC . This study enrol two stage . The first stage study enroll approximately 30 subject , time enrollment pause . An analysis safety tolerability review safety review committee ( SRC ) subject enrolled Stage 1 reach Week 4 . The SRC review determine safety tolerability profile GSK2248761 support continuation trial enrollment additional 120 subject . All subject continue study medication Week 4 analysis . Additional analysis conduct subject complete Week 4 , Week 16 , Week 24 Week 48 . A second review safety tolerability GSK2248761 perform SRC subject reach Week 4 . There pause study Week 4 analysis subject . The Week 16 Week 24 analysis use respectively select confirm optimal dose GSK2248761 continuation . This dose select base statistical analysis antiviral activity , safety tolerability criterion . If , confirmation optimal dose GSK2248761 Week 24 analysis , dose consider acceptable base efficacy , safety PK data , arm continue Week 48 . Beyond Week 48 , subject randomize non-selected dose GSK2248761 meet criteria discontinuation give option switch select dose GSK2248761 discontinue permanently study . Once switch select dose Open-Label phase study Week 96 . After Week 96 , subject receive GSK2248761 give option continue receive GSK2248761 locally approve commercially available , long continue derive clinical benefit without protocol-defined reason discontinuation . Subjects randomize EFV option continue receive EFV Week 96 unless meet protocol-defined reason discontinuation . All subject option continue TDF/FTC ABC/3TC Week 96 . After Week 96 , subject expect obtain local access commercially available ART . Randomization stratify : - HIV-1 RNA &lt; &gt; / 100,000 copies/mL screen - Use ABC/3TC TDF/FTC FDC tablets initial background ART Switch background NRTI toxicity management alternative market NRTI allow . Switches background NRTI reason permit study . A switch GSK2248761 EFV allow . Study Endpoints /Assessments : Subjects assessment perform include baseline demographic , disease characteristic , safety ( laboratory clinical evaluation ) . On study safety , efficacy , virologic , immunologic , PK evaluation conduct . Primary Endpoint : The proportion subject HIV-1 RNA &lt; 50copies/mL Week 16 . Dose selection base primarily antiviral activity tolerability conjunction immunologic , safety , virologic resistance PK measure . Data Week 24 analysis use confirm dose selection . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infect adult great equal 18 year age . A female eligible enter participate study ( 1 ) Nonchildbearing potential , ( 2 ) Childbearing potential , negative pregnancy test screen Day 1 agrees use protocolspecified method birth control study HIV1 infection screen plasma HIV1 RNA great equal 1000 copies/mL CD4+ cell count great equal 200 cells/mm3 Antiretroviralnaive Any preexist physical mental condition ( include substance abuse disorder ) , opinion Investigator , may interfere subject 's ability comply dose schedule and/or protocol evaluation may compromise safety subject Any condition , opinion Investigator , may interfere absorption , distribution , metabolism excretion drug render subject unable take oral medication Women currently breastfeed Any evidence active Centers Disease Prevention Control ( CDC ) Category C disease [ CDC,1993 ] , except cutaneous Kaposi 's sarcoma require systemic therapy History ongoing clinically relevant hepatitis within previous 6 month , include chronic hepatitis B virus ( HBV ) infection ( HBsAg positive ) . Asymptomatic individual chronic hepatitis C virus ( HCV ) infection exclude , however Investigators must carefully assess therapy specific HCV infection require ; subject anticipate require therapy randomize portion study must exclude History liver cirrhosis without hepatitis viral coinfection Ongoing clinically relevant pancreatitis History follow cardiac disease : myocardial infarction , congestive heart failure , document hypertrophic cardiomyopathy , sustain ventricular tachycardia Personal know family history prolong QT syndrome History presence allergy intolerance study drug component , history drug allergy , opinion Principal Investigator , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol Evidence viral resistance antiviral drug indicative primary transmit resistance screen historical resistance test result Any acute laboratory abnormality screening , , opinion Investigator , would preclude subject 's participation study investigational compound . Any verified Grade 4 laboratory abnormality screen would exclude subject study participation unless Investigator provide compel explanation laboratory result ( ) assent Medical Monitor Any follow laboratory value screen : ( 1 ) Creatinine clearance &lt; 50 mL/min via CockroftGault method , ( 2 ) Alanine aminotransferase ( ALT ) great equal 5 time upper limit normal ( ULN ) . Subjects ALT &gt; 2x ULN &lt; 5xULN may participate study , opinion Investigator GSK Medical Monitor lab abnormality interfere study procedure compromise subject safety , ( 3 ) Alanine aminotransferase ( ALT ) great equal 3xULN bilirubin great equal 1.5xULN ( &gt; 35 % direct bilirubin ) Any clinically significant find screen ECG , specifically ( single repeat allow determine eligibility ) : ( 1 ) Heart rate &lt; 45 &gt; 100 beat per minute ( bpm ) ( male ) ; &lt; 50 &gt; 100 bpm ( female ) . Note : A heart rate 100 110 bpm rechecked within 30 minute verify eligibility , ( 2 ) QRS duration &gt; 120 msec , ( 3 ) QTc interval &gt; 450 msec ( 4 ) Nonsustained ( great equal 3 consecutive beat ) sustain ventricular tachycardia , ( 5 ) Sinus pause &gt; 2.5 second , ( 6 ) 2nd degree ( Type II ) high AV ( Atrioventricular ) block , ( 7 ) Evidence WPW ( Wolff ParkinsonWhite ) syndrome ( ventricular preexcitation ) , ( 8 ) Pathologic Q wave ( define Q wave &gt; 40 msec OR depth &gt; 0.4 mV ( 9 ) Any abnormality opinion Investigator would interfere safety subject Treatment follow agent within 28 day prior screen , anticipated need agent study ( 1 ) Radiation therapy cytotoxic chemotherapeutic agent , ( 2 ) Immunomodulators ( systemic corticosteroid , interleukin , interferon ) Note : Subjects use shortterm ( &lt; 7 day ) steroid taper inhale corticosteroid eligible enrollment ( 3 ) Any nonprotocolspecified agent document activity HIV 1 vitro Treatment HIV1 immunotherapeutic vaccine within 90 day prior screen Receipt experimental drug and/or vaccine within 28 day 5 halflives , twice duration biological effect experimental drug vaccine , whichever longer , prior screen Immunization within 28 day prior first dose IP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>antiretroviral</keyword>
	<keyword>HAART</keyword>
	<keyword>NNRTI</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>Sexually Transmitted Disease</keyword>
	<keyword>antiretroviral therapy ( ART ) -naive adult</keyword>
	<keyword>Immunologic Deficiency Syndrome</keyword>
	<keyword>tenofovir</keyword>
	<keyword>abacavir</keyword>
	<keyword>Retroviridae Infections</keyword>
	<keyword>GSK2248761</keyword>
	<keyword>lamivudine</keyword>
	<keyword>Acquired ImmunoDeficiency Syndrome ( AIDS )</keyword>
	<keyword>HIV infection</keyword>
	<keyword>efavirenz</keyword>
</DOC>